Amyotrophic lateral sclerosis (ALS) is a devastating neurological disorder characterized by selective degeneration of upper and lower motoneurons. The primary triggers for motoneuron degeneration are still unknown, but inflammation is considered an important contributing factor. P2X7 receptor is a key player in microglia response to toxic insults and was previously shown to increase pro-inflammatory actions of SOD1-G93A ALS microglia. We therefore hypothesized that lack of P2X7 receptor could modify disease features in the SOD1-G93A mice. Hetero-and homozygous P2X7 receptor knock-out SOD1-G93A mice were thus generated and analysed for body weight, disease onset and progression (by behavioural scores, grip and rotarod tests) and survival. Although the lifespan of P2X7 1/2 and P2X7 2/2 /SOD1-G93A female mice was extended by 6 -7% with respect to SOD1-G93A mice, to our surprise the clinical onset was significantly anticipated and the disease progression worsened in both male and female P2X7
INTRODUCTION
Amyotrophic lateral sclerosis (ALS) is a late-onset neurodegenerative disease characterized by a progressive loss of motoneurons in the brain and spinal cord, resulting in muscle impairment. Patients eventually become paralysed and 50% die within 3 -5 years from symptoms onset, usually as the result of respiratory failure (1, 2) . Ninety per cent of patients do not have family members with ALS and are referred to as sporadic ALS cases; 10% of ALS patients have an inherited form which is commonly referred to as familial ALS (fALS) (3) . One form of fALS is caused by missense mutations in the gene encoding the enzyme Cu 2+ /Zn 2+ superoxide dismutase (SOD1), which induce a gain of toxic function (4, 5) . Since transgenic mice overexpressing the different mutated SOD1 proteins found in fALS develop a chronic progressive motoneuron disease resembling the clinical and pathological features of ALS, they serve as appropriate animal models for ALS (6) . Although numerous pathological pathways appear to contribute to motoneuron injury in this inexorable disease, a strong neuroinflammatory reaction mainly characterized by the presence of reactive microglia is an important pathological hallmark of ALS, being one of the major microscopic evidence present in spinal cord sections from post-mortem ALS patients (7) . The same inflammatory responses seen in ALS patients are also observed in mutated SOD1 mice, including activated microglia and astrocytes, infiltrating lymphocytes, monocytes/macrophages, dendritic cells and increased expressions of cytokines and chemokines (8 -12) .
Microglia, the resident immune effector cells in the central nervous system (CNS), display functional plasticity during activation, characterized by changes in cell number, morphology, surface receptors and production of growth factors and cytokines (13) . On the basis of their intrinsic properties, interactions with the cellular microenvironment and the presence of pathogenic factors, microglia can promote neuronal death (M1 microglia) by secreting pro-inflammatory cytokines, superoxide radicals, nitric oxide, but they can also play important roles in tissue repair and remodelling (M2 microglia) (14) . This inflammatory reaction, which is supposed to combat the initial neuronal insult, is believed to turn into a hazardous process and eventually contribute to neuronal damage (15) . A wide range of factors has been suggested to induce a neuroinflammatory response in patients with ALS and to mediate the detrimental or beneficial effects of glial cells on motoneurons (7) . Among these, extracellular ATP acting via the P2X7 receptor might be a good candidate to influence disease progression, since it was demonstrated in vitro that activation of P2X7 receptor in ALS-microglia exacerbates pro-inflammatory responses such as NADPH oxidase 2 (NOX2 or gp91 phox ) activity, TNF-a, COX-2, MAPKs levels and toxicity towards neuronal cells (16, 17) .
In order to elucidate an involvement of P2X7 receptor in ALS pathogenesis, we generated double-transgenic mice carrying the human SOD1-G93A mutation and lacking the endogenous P2X7 receptor gene. Hetero-and homozygous knock-out (KO) for P2X7 receptor SOD1-G93A mice (P2X7 +/2 /SOD1-G93A and P2X7
2/2 /SOD1-G93A) were compared with SOD1-G93A mice in terms of body weight, disease onset, motor performance and survival. We further studied the effects produced by the lack of P2X7 on motoneuron loss, gliosis and expression of NOX2, inducible nitric oxide synthase (iNOS) and MAPKs in mice spinal cord. Although the survival of P2X7
2/2 /SOD1-G93A females was extended by 7% with respect to SOD1-G93A mice, to our surprise, the clinical onset was significantly anticipated and disease progression worsened in terms of motor behaviour, gliosis, activation of inflammatory pathways and motoneuron loss in P2X7 2/2 /SOD1-G93A male and female mice.
RESULTS
Ablation of P2X7 receptor, mainly expressed in microglia in the SOD1-G93A mice spinal cord, does not modify SOD1 content
Before characterizing the phenotype resulting from the ablation of P2X7 receptor in SOD1-G93A mice, we verified the localization of P2X7 in SOD1-G93A mice lumbar spinal cord, as this is the CNS tissue predominantly damaged during ALS and thus chosen as target of our studies. As shown by doubleimmunofluorescence in Figure 1A , P2X7 colocalized with the microglia marker Iba-1 but not with the neuronal marker Neuronal Nuclei (NeuN), nor with the astrocytic marker glial fibrillary acidic protein (GFAP). Next, we analysed the content of P2X7 protein in P2X7
and P2X7 2/2 mice spinal cord. As shown by western blot in Figure 1B , the 80 kDa protein band corresponding to P2X7 receptor was reduced by 50% in P2X7 heterozygous mice with respect to wild-type (WT) mice, and was absent in P2X7KO mice.
Finally, in order to exclude that the absence of P2X7 receptor in SOD1-G93A mice might in some way alter the transgenic SOD1 protein content and consequently modify the ALS phenotype, we verified by western blot that the amount of human SOD1 in spinal cord was comparable between SOD1-G93A and P2X7
2/2 /SOD1-G93A mice (Fig. 1C) .
P2X7
1/2 /SOD1-G93A mice display no differences in body weight, disease onset and motor performance, but show significant survival increase in females, with respect to SOD1-G93A mice
We next proved that the deletion of P2X7 receptor per se did not cause any alteration of motor performance, by analysing P2X7KO and WT mice by rotarod test (data not shown). With the aim to characterize the lack of P2X7 on ALS pathogenesis, we then analysed heterozygous P2X7 +/2 /SOD1-G93A mice. Body weight loss started around week 17; it became significant with respect to WT at week 18 in both SOD1-G93A and P2X7
+/2 /SOD1-G93A mice, with no significant difference between transgenic groups until end-stage ( Fig. 2A) . Motor performance assessed by rotarod test in order to evaluate both onset of symptoms (at week 19) and further progression of motor deficit was again not statistically different between genders and groups, although it tended to worsen in P2X7 +/2 / SOD1-G93A compared with SOD1-G93A mice (Fig. 2B) . In spite of this, P2X7
+/2 /SOD1-G93A females survived significantly longer (169 versus 160 days, 6% increase) compared with SOD1-G93A female mice (Fig. 2C) , with no differences found in male mice (168 versus 162 days) (Fig. 2D ).
2/2 /SOD1-G93A mice anticipate onset and display a worsened disease progression, but show extended lifespan in females, with respect to SOD1-G93A mice
We then studied the effects of full lack of P2X7 receptor in SOD1-G93A mice on ALS onset and progression. Despite body weight loss occurred in a comparable way in all SOD1-G93A-expressing phenotypes (Fig. 3A) , general animal conditions assessed by a 5 to 1 behavioural scoring system were significantly aggravated in P2X7 2/2 /SOD1-G93A mice (weeks 20 to 23) (Fig. 3B) . Median disease onset, quantified with a grip test, was significantly anticipated (105 versus 109 days) with respect to SOD1-G93A mice (Fig. 3C) . By the rotarod analysis, we confirmed that the onset of deterioration of motor performance (week 18) was anticipated by 1 week in doubletransgenic mice. They showed 40% decrease in rotarod performance at 20 and 21 weeks, which gradually reached 60% at late time points (23 weeks) with respect to SOD1-G93A mice (Fig. 3D ), without differences between genders in each group (i.e. at 20 weeks, rotarod performance was 15.6% for females versus 15.4% for males in P2X7 2/2 /SOD1-G93A mice, data not shown). However, P2X7
2/2 /SOD1-G93A female mice displayed a significant 7% increase in survival, with respect to SOD1-G93A female mice (171 versus 160 days) (Fig. 3E ). There were instead no significant differences between males belonging to the two groups (162 versus 162 days) (Fig. 3F) .
Lack of P2X7 receptor increases astrocytosis in SOD1-G93A mice at end-stage
Since we detected an evident functional and behavioural decline in P2X7
2/2 /SOD1-G93A with respect to SOD1-G93A mice at 20 weeks of age, we next examined whether this motor failure was associated with an increased gliosis occurring in the spinal cord. Immunofluorescence and confocal analysis for GFAP staining was performed on lumbar (L3 -L5) spinal cord sections Human Molecular Genetics, 2013, Vol. 22, No. 20 4103 of SOD1-G93A and P2X7 2/2 /SOD1-G93A mice and compared with age-matched WT and P2X7 2/2 mice, at both 20 weeks of age and end-stage (Fig. 4) . Although WT and P2X7 2/2 mice showed no differences in GFAP labelling ( Fig. 4A and B) , both SOD1-G93A groups revealed an increase in GFAP immunoreactivity when compared with WT and P2X7 2/2 mice, respectively, at both examined stages (Fig. 4C-G) . Interestingly, P2X7
2/2 / SOD1-G93A mice compared with SOD1-G93A mice showed an increasingly exacerbated astrocytosis that became evident only at end stage (1.7-fold increase) (Fig. 4A-G) , with a morphological transition from a typical ramified phenotype to a phenotype characterized by longer, thicker, fibrous and overlapping prolongements (insets in Fig. 4E and F) , typical of glial scar (18) . The up-regulation of GFAP was validated by western blot analysis, showing 1.6-fold increase in the expression of GFAP in P2X7 2/2 /SOD1-G93A group at end stage, with respect to SOD1-G93A mice (Fig. 4G ). There were no differences in the expression of GFAP between genders, in each analysed group (data not shown).
Lack of P2X7 receptor increases microgliosis in SOD1-G93A mice at end-stage Since previous studies have shown that P2X7 receptor is directly involved in microglia activation (19) , we next investigated +/2 /P2X7 2/2 90-day-old mice (n ¼ 3) were subjected to western blotting and immunoreactions with anti-P2X7 antibody. (C) Equal amounts of total lumbar spinal cord lysates (L3-L5) from WT, SOD1-G93A and P2X7
2/2 /SOD1-G93A 160-day-old mice (n ¼ 3) were subjected to western blotting and immunoreactions with anti-hSOD1. Anti-b-actin was used for protein normalization. Data represent means + SEM. Statistical significance was calculated by Student's t-test, * P , 0.05.
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Human Molecular Genetics, 2013, Vol. 22, No. 20 whether and to what extent the lack of the receptor could affect microglia at late stages of the disease. We analysed the expression of microglia morphological markers Iba-1 and CD68 by immunofluorescence and confocal analysis on spinal cord sections (L3 -L5) of SOD1-G93A and P2X7 2/2 /SOD1-G93A mice at both 20 weeks of age and end-stage, and compared them with age-matched WT and P2X7 2/2 mice (Figs 5 and 6). Although WT and P2X7 2/2 mice showed no differences in microglia staining (Figs 5A, B and G and 6A, B and G), both SOD1-G93A groups revealed an increase in the immunostaining of Iba-1 ( Fig. 5C -G) and CD68 ( Fig. 6C -G) compared with WT and P2X7 2/2 mice, at both stages of the disease. Surprisingly, the lack of P2X7 receptor in SOD1-G93A mice not only failed to prevent microgliosis, but also induced a remarkable end-stage increase in the labelling of both Iba-1 (1.6-fold) and CD68 (1.9-fold), with respect to SOD1-G93A mice ( Fig. 6E -G ). There were no differences between genders in each analysed group (data not shown). The over-expression of Iba-1 and CD68 in end-stage P2X7 2/2 /SOD1-G93A mice was confirmed also by western blot analysis, showing an increase, respectively, of 1.2-fold ( Fig. 5H ) and 2-fold ( Fig. 6H ), compared with SOD1-G93A mice.
P2X7 ablation enhances microglia inflammatory markers in SOD1-G93A mice
In order to study whether the changes in microglia morphological markers of activation (Iba-1 and CD68) reflected an enhanced pro-inflammatory state, we next analysed the functional cytotoxic markers NOX2 and iNOS (20) . Immunofluorescence and western blot analysis for gp91 phox and iNOS was performed on the lumbar spinal cord of WT, SOD1-G93A and P2X7
2/2 /SOD1-G93A endstage mice. As shown in Figure 7A , gp91 phox colocalized with Iba-1 and was up-regulated in P2X7
2/2 /SOD1-G93A compared with SOD1-G93A mice (2.5-fold) ( Fig. 7A and B) . As shown in Figure 7D , also iNOS mainly colocalized with CD11b and was up-regulated in P2X7
2/2 /SOD1-G93A compared with SOD1-G93A mice (2-fold) ( Fig. 7D and E). gp91 phox and iNOS overexpression in P2X7
2/2 /SOD1-G93A mice was also confirmed by western blot, showing a 2-fold and 1.4-fold increase, respectively (Fig. 7C ).
Increased motoneuron loss in P2X7
2/2 /SOD1-G93A mice
We then counted motoneurons in lumbar spinal cord sections stained with cresyl violet (L3 -L5) of WT, P2X7 2/2 , Figure 2 . Comparable body weight, disease onset and motor performance, but extended female survival in P2X7 +/2 /SOD1-G93A mice. Body weight (A) and rotarod test (B) of SOD1-G93A and P2X7
+/2 /SOD1-G93A compared with WT mice. No statistically significant differences were observed between transgenic groups. (C) The graph represents the probability of survival of female SOD1-G93A mice (n ¼ 10) and female P2X7 +/2 /SOD1-G93A mice (n ¼ 14). Median survival was significantly different (160 versus 169 days; Kaplan -Meier survival curves;
* P ≤ 0.05). (D) The graph represents the probability of survivals of male SOD1-G93A mice (n ¼ 10) and male P2X7 +/2 /SOD1-G93A mice (n ¼ 14). Median survivals were not significantly different (162 versus 168 days; KaplanMeier survival curves; P . 0.05)
SOD1-G93A and P2X7
2/2 /SOD1-G93A mice. As expected, P2X7 2/2 mice showed no differences in motoneuron number compared with WT mice (Fig. 8A and B) , both displaying healthy motoneurons (21, 22) with large cell bodies (.200 mm 2 ) rich in Nissl substance, broad proximal dendrites extending from the perikaryon (arrow) and large nucleus with a prominent nucleolus (white star) (inset in Fig. 8B ). In both SOD1-G93A groups, motoneurons were significantly reduced by 40% at 20 weeks (Fig. 8C , D and G). At end-stage, motoneurons displayed an evident loss of Nissl substance, formation 2/2 /SOD1-G93A mice. No differences in the loss of body weight (A) but worsened general conditions were observed between SOD1-G93A and P2X7
2/2 /SOD1-G93A mice compared with WT mice (B) ( * P ≤ 0.05 for the comparison of SOD1-G93A mice with P2X7 2/2 /SOD1-G93A). (C) Onset of disease was assessed by grip test using Kaplan-Meier curves for comparing onset probability between SOD1-G93A and P2X7
2/2 /SOD1-G93A groups (105 versus 109 days; * P ≤ 0.05) and by rotarod test (D) ( # P ≤ 0.05 for the comparison of P2X7 2/2 / SOD1-G93A mice with WT). P2X7
2/2 /SOD1-G93A showed a decrease in rotarod performance with respect to SOD1-G93A mice (D) ( * P ≤ 0.05). (E) The graph represents the probability of survival of female SOD1-G93A mice (n ¼ 10) and female P2X7 -/-/SOD1-G93A mice (n ¼ 14). Median survival was significantly different (160 versus 171 days; Kaplan-Meier survival curves;
* P ≤ 0.05) (F) P2X7
-/-/SOD1-G93A males (n ¼ 14) showed no differences in median survival with respect to SOD1-G93A males (n ¼ 10) (162 versus 162; Kaplan-Meier survival curves).
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of vacuoles in the cell body (arrowhead), shrinkage of proximal dendrites (arrow), displacement and condensation of the nucleus (white star) (inset in Fig. 8F ). All these features appeared more pronounced in P2X7 2/2 /SOD1-G93A mice ( Fig. 8E and F ) and, consistently, motoneuron loss was significantly increased by 40% with respect to SOD1-G93A mice (Fig. 8G ). There were no differences between genders in each analysed group (i.e. in P2X7 2/2 /SOD1-G93A mice, at 20 weeks there was a 39.5% motoneuron reduction for females versus 41.7% for males, at end stage 78.5% for females versus 77.3% for males, data not shown). Motoneuron loss in animals at disease end-stage was also confirmed by immunofluorescence and confocal microscopy have no differences (grid bar) when compared with WT mice (white bar), but at 20 weeks (20 we) of age, SOD1-G93A mice (grey bar) and P2X7 2/2 / SOD1-G93A (black bar) show comparable GFAP optical density increase. At end stage (e.s.), GFAP signal is significantly higher in P2X7 2/2 /SOD1-G93A mice compared with SOD1-G93A mice (n ¼ 4-5/genotype). (H) Equal amounts of total lumbar spinal cord lysates (L3-L5) from WT, SOD1-G93A and P2X7
2/2 / SOD1-G93A end-stage mice (n ¼ 4) were subjected to western blotting and immunoreactions with anti-GFAP and anti-b-actin for protein normalization. Data represent mean + SEM. Statistical significance was calculated by Student's t-test referred to WT, * P , 0.05, or to SOD1-G93A, # P , 0.05.
Human Molecular Genetics, 2013, Vol. 22, No. 20 4107 performed on lumbar spinal cord sections of WT, SOD1-G93A and P2X7 2/2 /SOD1-G93A mice with anti-NeuN antibody. This neuronal marker primarily stains cell nuclei, although a slightly lighter staining is also visible in the neuronal cytoplasm (23) . As shown in Figure 8H -L, the number of motoneurons, identified as cells with largest soma sizes (24) , markedly decreased in P2X7 2/2 /SOD1-G93A with respect to SOD1-G93A mice.
Significant differences in MAPK levels in P2X7 2/2 / SOD1-G93A mice Since P2X7 receptor is known to be involved in the activation of different inflammatory signalling pathways in SOD1-G93A microglia, including MAPKs (17), we investigated the effect produced by P2X7 deletion on the expression of these kinases, 2/2 have no differences (grid bar) when compared with WT mice (white bar), but at 20 weeks (20 we) of age SOD1-G93A mice (grey bar) and P2X7
2/2 /SOD1-G93A mice (black bar) show comparable increase in Iba-1 optical density. At end stage (e.s.), Iba-1 signal is significantly higher in P2X7 2/2 /SOD1-G93A mice compared with SOD1-G93A mice (n ¼ 4 -5/genotype). (H) Equal amounts of total lumbar spinal cord lysates (L3-L5) from WT, SOD1-G93A and P2X7
2/2 /SOD1-G93A end-stage mice (n ¼ 4) were subjected to western blotting and immunoreactions with anti-Iba-1 and anti-b-actin for protein normalization. Data represent mean + SEM. Statistical significance was calculated by Student's t-test referred to WT, * P , 0.05, or to SOD1-G93A, # P , 0.05.
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Human
by analysing the levels of basal and activated ERK1/2, p38 and JNK in lumbar spinal cord homogenates of end-stage animals. By western blotting (Fig. 9A) , we demonstrated that the levels of p-ERK1/2, p-p38 and p-JNK were significantly increased in both SOD1-G93A transgenic mice, compared with WT mice, with a significant further up-regulation occurring in P2X7 2/2 /SOD1-G93A, with respect to SOD1-G93A mice (Fig. 9B) . Although in P2X7
2/2 /SOD1-G93A mice also the content of total ERK1/2 was higher with respect to WT animals, the level of p-ERK/ERK remained significantly augmented, indicating therefore that in these animals an increase in the level of both total and phosphorylated protein occurred (Fig. 9B) . The same changes did not take place in the case of p38 and JNK, where the total protein levels remained constant in P2X7 2/2 /SOD1-G93A compared with SOD1-G93A mice (data not shown). 2/2 have no differences (grid bar) when compared with WT mice (white bar), but at 20 weeks (20 we) of age SOD1-G93A mice (grey bar) and P2X7
2/2 /SOD1-G93A mice (black bar) show comparable increase in CD68 optical density. At end stage (e.s.), CD68 signal is significantly higher in P2X7 2/2 /SOD1-G93A mice compared with SOD1-G93A mice (n ¼ 4 -5/genotype). (H) Equal amounts of total lumbar spinal cord lysates (L3-L5) from WT, SOD1-G93A and P2X7
2/2 /SOD1-G93A end-stage mice (n ¼ 4) were subjected to western blotting and immunoreactions with anti-CD68 and anti-b-actin for protein normalization. Data represent mean + SEM. Statistical significance was calculated by Student's t-test referred to WT, * P , 0.05, or to SOD1-G93A, # P , 0.05.
DISCUSSION
With this work, we illustrate a clear involvement of the P2X7 receptor with one rare but distressing pathology of the nervous system, that is ALS, since so far only preliminary studies and correlative data were available emphasizing the role of this receptor in this motoneuron dysfunction (25) . It was indeed reported that ALS patients and SOD1-G93A animals possess increased immunoreactivity for P2X7 protein in spinal cord microglia (26, 27) . Furthermore, SOD1-G93A microglia in Figure 7 . Inflammatory microglia markers are increased in P2X7 2/2 /SOD1-G93A mice. Spinal cord sections (L3-L5) from WT (insets), SOD1-G93A and P2X7 2/2 / SOD1-G93A mice at end-stage were double-immunostained with anti-gp91 phox (green) and anti-Iba-1 (red) (A) or with anti-iNOS (green) and anti-CD11b (red) (D). In merged panels is shown the presence of gp91 phox (A) and iNOS (D) in microglial cells (yellow). Scale bar ¼ 40 mm, insets ¼ 100 mm. P2X7 2/2 /SOD1-G93A mice showed an increase in both inflammatory markers compared with SOD1-G93A mice (n ¼ 4-5/genotype) (B-E). (C) Equal amounts of total lumbar spinal cord lysates (L3-L5) from WT, SOD1-G93A and P2X7
2/2 /SOD1-G93A end-stage mice (n ¼ 4) were subjected to western blotting and immunoreactions with anti-gp91 phox , anti-iNOS and anti-b-actin for protein normalization. Data represent mean + SEM. Statistical significance was calculated by Student's t-test referred to WT, * P , 0.05, or to SOD1-G93A, # P , 0.05.
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Human Molecular Genetics, 2013, Vol. 22, No. 20 culture display augmented sensitivity to ATP, and P2X7 receptor activation drives a pro-inflammatory pathway leading to decreased survival of neuronal cell lines (16) . Finally, P2X7 activation in astrocytes from the spinal cord of SOD1-G93A mice also initiates a neurotoxic phenotype that turns into motoneuron death (28) . Thus, the possibility that P2X7 receptor could modify in some aspects the course of ALS, as we tested with the present work, was in a way predictable because of these in vitro inflammatory actions exerted by direct activation of the receptor especially in microglia and astrocytes. Here we show that genetic ablation of P2X7 protein in the so far best characterized model of ALS, the SOD1-G93A mouse, significantly affects disease 2/2 /SOD1-G93A (D) at 20 weeks, and SOD1-G93A (E) and P2X7 2/2 /SOD1-G93A mice (F) at end-stage were stained with cresyl violet to assess motoneuron numbers. Scale bar ¼ 100 mm. At higher magnification (insets), P2X7 2/2 motoneurons show cell bodies rich in Nissl substance, broad proximal dendrites extending from the perikaryon (arrow) and large nucleus with a defined nucleolus (white star). In contrast, P2X7
2/2 /SOD1-G93A motoneurons display an evident loss of Nissl substance, vacuolization (arrowhead), proximal dendrites shrinkage (arrow) and displacement and condensation of the nucleus (white star). Scale bar ¼ 10 mm. (G) Quantitative analysis of motoneurons counts in the ventral horn of spinal cord shows that P2X7 2/2 have no differences in motoneurons number (grid bar) when compared to WT mice (white bar), but at 20 weeks of age SOD1-G93A mice (grey bar) and P2X7 2/2 /SOD1-G93A mice (black bar) show similarly reduced motoneurons number. At end stage (e.s.) in P2X7
2/2 /SOD1-G93A, there is a further loss of motoneurons compared with SOD1-G93A mice (n ¼ 4-5/genotype) (t-test referred to WT, # P , 0.05, or to SOD1-G93A, * P , 0.05). Motoneurons of spinal cord sections (L3-L5) from WT (H), SOD1-G93A (I) and P2X7 2/2 / SOD1-G93A (L) mice at end stage stained with anti-NeuN (scale bar ¼ 40 mm).
onset, progression and survival. We demonstrated that partial and, even more, total ablation of P2X7 receptor prolongs the survival of female mice. This gender-specific difference is consistent with lower mortality generally found in females in various double-transgenic ALS mice models (29) (30) (31) (32) . Although the molecular mechanisms are not fully understood (33) , this effect is generally ascribed to the protective action of oestrogens. Moreover, it was reported that female mice live longer than males in several different congenic SOD1-G93A lines with SJL/J, C3H/ HeJ, BALB/cByJ, FVB, but not C57BL/6N background (34) (35) (36) . Since P2X7 2/2 /SOD1-G93A mice are on C57BL/6N background, we can therefore exclude a strain-dependent effect on survival. Moreover, we demonstrated that the pro-survival action exerted by ablation of P2X7 is not associated with any improvement of general conditions, symptoms onset and motor performance, which are instead significantly worsened in homozygous P2X7
2/2 /SOD1-G93A mice (with a similar tendency in heterozygous conditions) without any gender difference, implying therefore a longer disease duration in females. These results were corroborated by increased gliosis, together with augmented neuronal loss, as detected by examination of the lumbar spinal cord. Actually, at end stage, the deletion of P2X7 receptor is associated with highly increased GFAP, Iba-1 and CD68 immunoreactivity and concomitant decrease in motoneuron number.
However, the lack of difference in these parameters between P2X7 2/2 /SOD1-G93A and SOD1-G93A mice at earlier stage could be explained by the well-known retrograde progression of ALS-linked damage (37) that might not allow to clearly evince further morphological alterations at CNS level. As a first conclusion, the results obtained from our analysis of P2X7 2/2 /SOD1-G93A mice highlight a 2-fold outcome on survival and disease progression, suggesting that the specific involvement of P2X7 receptor in ALS is not univocal and perhaps affects different molecular and systemic levels. This is not surprising, especially in consideration of the multifactorial and multisystemic nature of ALS (38) . However, at this stage we cannot exclude the amelioration of additional parameters, or a protective effect at the level, for instance, of the brain or blood circulating cells as macrophages and T-cells.
In order to define a possible mechanism by which the lack of P2X7 determines the events described above, it is of importance to clarify the receptor localization in the spinal cord. Data from the literature report that in the mouse spinal cord, P2X7 receptor is predominantly expressed by microglia (39) (40) (41) , whereas its presence was demonstrated only in vitro in astrocytes (42) (43) (44) , and very controversially in motoneurons (40, 45, 46) . Furthermore, in the spinal cord from SOD1-G93A rats and post-mortem ALS patients, the P2X7 receptor is localized only in microglial 2/2 /SOD1-G93A end-stage mice (n ¼ 4 for each genotype) were subjected to western blotting and immunoreactions with anti-p-ERK1/2, -ERK1/2, -p-p38 and -p-JNK; anti-b-actin was used for protein normalization. (B) Up-regulation of p-ERK1/2, p-p38 and p-JNK was found in transgenic mice compared with WT and these were increased in P2X7 2/2 /SOD1-G93A compared with SOD1-G93A. ERK1/2 was significantly up-regulated in P2X7 2/2 /SOD1-G93A compared with WT. Data represent means + SEM (t-test referred to WT, * P , 0.05, or to SOD1-G93A, # P , 0.05).
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Human 26, 27) . With our work, we confirmed a main microglial distribution of the receptor also in the SOD1-G93A mice spinal cord. Since the recent work by Audet et al. (47) proved that ablation of proliferating microglia exacerbates motoneuron disease caused by mutant SOD1, from our results we can therefore suppose that the exacerbated gliosis and neurodegeneration found in the spinal cord of P2X7 2/2 /SOD1-G93A mice may arise mainly from the lack of P2X7 receptor in microglia. As a matter of fact, we demonstrated an evident up-regulation in P2X7
2/2 /SOD1-G93A microglia of two important neuroinflammatory and cytotoxic mediators, e.g. NOX2 and iNOS, already known to be detrimental in ALS (20) . Moreover, we found a further activation of the MAPKs pathway in the spinal cord of P2X7 2/2 /SOD1-G93A mice by augmented pERK/ ERK, p-p38 and p-JNK levels. This phenomenon correlates with increased gliosis, inflammation and neuronal degeneration found in end-stage spinal cord of P2X7 2/2 /SOD1-G93A mice. We can therefore hypothesize that it might partake in the increased pro-inflammatory response, as the MAPKs are also involved in NOX2 and iNOS signalling pathways (17, 48, 49) , as well as in neuronal death, since JNK/p38 pathways are aberrantly activated in SOD1-G93A dying motoneurons (50) (51) (52) . However, during ALS progression, microglia activation, which occurs before evident motoneuron damage and well before clinical disease onset (9) , is known to be a double-edged sword, with the ability to promote both neuronal protection (M2 microglia) and injury (M1 microglia) (15) . On the C57BL/6N background, this transformation occurs around 16 -18 weeks, as the rate of disease progression accelerates (15, 53) . Our studies showing that deletion of P2X7 receptor function indeed exacerbates behavioural, motor performance, morphological and functional inflammatory markers and motoneuron degeneration might thus suggest a trophic and/or reparative role of this receptor in at least some phases of the disease. Referred to microglia in particular, its absence might impair the function of protective M2 microglia and thus determine a boost of detrimental neuroinflammatory responses as shown by the increase of typical M1 markers NOX2 and iNOS. However, in explaining the symptomatic worsening of P2X7 2/2 /SOD1-G93A mice, we should also consider a mechanism potentially involving the participation of additional P2 receptors. Among these, in particular, the P2X4 subunit could be a strong candidate, being often co-expressed with P2X7 protein also in ALS microglia (16) , and being up-regulated in P2X7KO models (54, 55) . Conversely, this hypothesized trophic role of P2X7 as effector of M2 microglia would seem to be in contrast with our previous findings obtained in SOD1-G93A microglia primary cultures, where the receptor instead exhibits a clear detrimental role, activating typical M1 parameters such as NOX2 and TNFa (16) . Owing to the well-known non-cell autonomous nature of ALS (56) , an explanation for this discrepancy could be that under experimental conditions where SOD1-G93A primary microglia is not surrounded by astrocytes and neurons, the sustained stimulation of P2X7 occurring in vitro might promote the M1 phenotype. In the in vivo ALS model, P2X7 could instead be protective at least in the early phases of the disease, when the damage is still limited. The dual role of P2X7 receptor is furthermore consistent with the two components of the P2X7 receptor-associated current and the opposite effects that P2X7 receptor exerts on cellular functions, such as pro-cell growth and differentiation (occupancy of two ATP-binding sites) versus pro-cell death (occupancy of three ATP-binding sites accompanied by pore dilation) (57) . Thus, much information has still to be gathered in order to fully understand the P2X7 receptor-dependent sequence of events in promoting and sustaining the ALS pathological insult to the nervous system. Conditional P2X7KO SOD1-G93A mice or pharmacological treatment of SOD1-G93A mice with P2X7-specific antagonists at different stages of the disease will next contribute to shed light on this issue.
In conclusion, with this work we have illustrated clear implications of P2X7 receptor engagement in ALS, demonstrating by its deletion in SOD1-G93A mice that the receptor might indeed act as a genetic modifier, according to its capability of affecting disease progression through the induction of microgliosis, astrocytosis, inflammatory pathways and exacerbating motoneuron degeneration.
MATERIALS AND METHODS

Mice
Adult B6.Cg-Tg(SOD1-G93A)1Gur/J mice expressing high copy number of mutant human SOD1 with a Gly93Ala substitution (SOD1-G93A) and B6.129P2-P2rx7tm1Gab/J mice (P2X7 2/2 ) were originally obtained from Jackson Laboratories (Bar Harbor, ME, USA) and bred in the indoor animal facility. In order to generate SOD1-G93A mice lacking P2X7 receptor (P2X7 2/2 /SOD1-G93A), transgenic hemizygous SOD1-G93A males were first cross-bred with P2X7 2/2 females, both maintained on the C57BL/6 genetic background, to generate F1 progeny (P2X7 +/2 /SOD1-G93A) and, afterwards, P2X7 +/2 / SOD1-G93A males were cross-bred with P2X7 2/2 females to obtain the F2 progeny (P2X7 2/2 /SOD1-G93A). Animals were housed at constant temperature (22 + 18C) and relative humidity (50%), with a regular 12 h light cycle (light 7 AM-7 PM), throughout the experiments. Food and water were freely available. When animals started to fail the rotarod test (see what follows), macerated food was given daily for easy access to nutrition and hydration. All animal procedures were performed according to the European Guidelines for the use of animals in research (86/609/ CEE) and the requirements of Italian laws (D.L. 116/92). The ethical procedure has been approved by the Animal Welfare Office, Department of Public Health and Veterinary, Nutrition and Food Safety, General Management of Animal Care and Veterinary Drugs of the Italian Ministry of Health. All efforts were made to minimize animal suffering and to use the number of animals only necessary to produce reliable results.
Transgenic progeny was genotyped analysing tissue extracts from tail tips according to the following procedure. Briefly, tail tips were digested (overnight, 558C) in tail buffer (100 mM Tris -HCl, pH 8, 0.5% Tween 20, 0.5% NP40) plus 200 mg/ml Proteinase K, and then heated at 758C for 20 min to inactivate Proteinase K. The presence of P2RX7 and/or SOD1-G93A mutant transgene was assessed by performing PCR on digested tail by using BioMix Red (Bioline) and the following primers: P2X7 forward 5 (60) . To determine disease onset, mice were subjected to grip test twice a week, starting at 70 days of age. Briefly, the following hanging wire test was used for the grip test: the mouse was placed on a wire grid (wire thickness, 2 mm) that was gently shaken to prompt the mouse to hold onto the wire and the grid was then turned upside down. The latency for the mouse to release the grid was recorded within three attempts for an arbitrary maximum of 90 s (61) . If a mouse dropped from the grid within 90 s in three consecutive trials, it was defined as symptomatic.
Rotarod performance was tested twice a week on a rotarod apparatus (Ugo Basile 7650 model) at a constant speed of 15 r.p.m. over a maximum of 180 s period, starting at 11 weeks of age until animals were unable to remain on the rotarod. After a training period of 3 days, the latency to fall off was recorded as a measurement of the competence to motor function. During each test day, the animals had three trials and the best performance was recorded and included in the data analysis (61).
Immunofluorescence and confocal microscopy
Mice were anaesthetized by intraperitoneal injection of chloral hydrate (500 mg/Kg) and transcardially perfused with 50 ml of PBS followed by 4% paraformaldehyde at pH 7.4. Tissue samples were then post-fixed overnight in 4% paraformaldehyde in PBS and then cryoprotected in 30% sucrose in PBS at 48C. Tissues were then stored at 2808C. Spinal cords (L3 -L5) were cut at 30 mm of thickness with a frozen microtome. The sections were mounted on slide glasses and allowed to air-dry (1-2 h). A rectangle was then drawn around the sections with a PAP pen (Sigma-Aldrich, Milan, Italy). The double-immunofluorescence analysis was performed according to the following procedure. Sections were then blocked in PBS containing 10% normal donkey serum and 0.3% Triton X-100 for 1 h at room temperature. Spinal cord sections were incubated with either mouse monoclonal GFAP (1:10, AbD Serotech, Oxford, UK), rabbit polyclonal anti-Iba1 (1:200, Wako, Richmond, VA, USA), monoclonal rat anti-CD68 (1:100, AbD Serotech), monoclonal rat anti-CD11b (1:200, AbD Serotech), mouse purified anti-gp91 phox (1:500, BD Transduction Laboratories, California, USA), rabbit polyclonal anti-NOS-2 (iNOS) (sc-650, 1:200, Santa Cruz Biotechnology, California, USA), mouse monoclonal anti-NeuN (1:200, Millipore, MA, USA) in PBS, 0.3% Triton X-100 and 2% normal donkey serum, for 24 h at 48C. Slides were washed with PBS and incubated with appropriate fluorescent-conjugated secondary antibodies for 3 h at room temperature. The secondary antibodies used were Cy3-conjugated donkey anti-rabbit immunoglobulin G (IgG) (1:100, Jackson ImmunoResearch, red immunofluorescence), Cy2-conjugated donkey anti-rabbit IgG (1:100, Jackson ImmunoResearch, green immunofluorescence), Cy2-conjugated donkey anti-mouse IgG (1:100, Alexa, Molecular Probes, Inc., Eugene, OR, USA, green immunofluorescence) or Cy3-conjugated donkey anti-rat IgG (1:100, Jackson ImmunoResearch, red immunofluorescence). For P2X7 receptor detection, anti-P2X7-ATTO-550 (1:20, Alomone Labs, Jerusalem, Israel) was used. PBS washes (3 × 5 min) were performed and slides were coverslipped with Fluoromount medium (SigmaAldrich). Immunofluorescence was analysed by means of a confocal laser scanning microscope (Zeiss, LSM700, Germany) equipped with four laser lines: 405, 488, 561 and 639 nm. The brightness and contrast of the digital images were adjusted using the Zen software (Zeiss). Quantification of immunofluorescence was performed on an average of six sections of the lumbar spinal cord for each animal in each group, measuring optical density by the Zen software (Zeiss).
Nissl staining
The tissue was processed as described earlier and serial spinal cord sections (n ¼ 12) from L3 -L5 were randomly selected and stained with 1% cresyl violet. Stained sections were dehydrated gradually in 50-100% alcohol, cleared in xylene and coverslipped with Eukitt (Sigma-Aldrich). The whole ventral horn of the spinal cord was photographed at ×20 magnification with Zeiss Axioskop 2 microscope. Large neurons, with cell bodies ≥200 mm 2 and a definable cytoplasm with a nucleus and nucleolus (22) , were then counted using the Neurolucida software (MBF Bioscience, USA).
Western blot
Protein lysates were obtained by homogenization of mice lumbar spinal cords segments in homogenization buffer (20 mM HEPES, pH 7.4, 100 mM NaCl, 1% Triton X-100, 10 mM EDTA) added with protease inhibitor cocktail (Sigma-Aldrich). After sonication, lysates were kept for 30 min on ice and then centrifuged for 20 min at 14 000g at 48C. Supernatants were collected and assayed for protein quantification with the Bradford detection kit (Bio-Rad Laboratories, Hercules, CA, USA). Separation of protein components was performed by Mini-PROTEAN w TGX TM Gels (Bio-Rad, USA) followed by transfer onto nitrocellulose membranes (Amersham Biosciences, Cologno Monzese, Italy). After saturation with ECL-Advance TM blocking agent (Amersham Biosciences), blots were probed overnight at 48C with the specific primary antibody. Primary antibodies used were mouse p44/42 MAPK (ERK1/2) (L34F12) (1:2000) , rabbit phospho-p44/42 MAPK (ERK1/2) (Thr202/Tyr204) (1:1000), SAPK/JNK (1:1000), phospho-SAPK/JNK (Thr183/Tyr185) (1:1000) and phospho-p38 MAPK (Thr180/Tyr182) (12F8) (1:500) from Cell Signaling Technology, Inc. (Beverly, MA, USA); mouse p-38 MAPK (A-12) (1:500, Santa Cruz Biotechnology); mouse GFAP (1:50, AbD Serotech); rabbit Iba-1 (1:500, Wako); mouse CD68 (1:100, Santa Cruz Biotechnology); mouse gp91 phox (1:1000, BD Transduction Laboratories); rabbit 
Statistical analysis
Data are presented as mean + standard error of the mean (SEM). Analysis was performed with the statistical software package MedCalc (Medcalc Software, Mariakerke, Belgium). Disease onset and survival were analysed with the Kaplan -Meier graph followed by log-rank statistics. Analysis of rotarod data was performed using ANOVA. Statistical differences between groups were verified by Student's t-test. * P , 0.05 was considered significant.
